Brief: Valbiotis Authorised For Phase 2 HEART Study In Reducing Cholesterol

Valbiotis SA

15/02/2021 17:10

Feb 15 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS AUTHORIZED TO LAUNCH HEART, THE PHASE II
MULTI-CENTER
CLINICAL STUDY WITH TOTUM-070, FOR THE REDUCTION OF BLOOD
LDL-CHOLESTEROL LEVELS
    * FAVORABLE OPINION OF CPP AND AUTHORIZATION FROM ANSM ALLOW
OPERATIONAL LAUNCH OF HEART STUDY
    * RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WILL
INCLUDE
120 PEOPLE WITH UNTREATED MILD TO MODERATE
LDL-HYPERCHOLESTEROLEMIA
    * FIRST VISIT OF FIRST PATIENT IN STUDY WILL BE REPORTED IN
AN
UPCOMING COMMUNICATION

Source text for Eikon:  ID:nBw8f5c2ra 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))